PRODUCT INFORMATION



Resolvin D1-d₅

Item No. 11182

CAS Registry No.: 1881277-32-2

7S,8R,17S-trihydroxy-4Z,9E,11E,13Z,15E,19Z-Formal Name:

21,21',22,22,22-d₅ docosahexaenoic acid

Synonyms: 17(S)-Resolvin D1-d₅, RvD1-d₅

MF: $C_{22}H_{27}D_5O_5$ 381.5 FW: Chemical Purity: ≥95%


Deuterium

Incorporation: \geq 99% deuterated forms (d₁-d₅); \leq 1% d₀

UV/Vis.: λ_{max} : 289, 302, 317 nm A solution in ethanol Supplied as:

Storage: -80°C Stability: ≥1 year Special Conditions: Light sensitive

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

Resolvin D1-d₅ (RvD1-d₅) is intended for use as an internal standard for the quantification of RvD1 (Item No. 10012554) by GC- or LC-mass spectrometry. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

 $RvD1-d_5$ is supplied as a solution in ethanol. To change the solvent, simply evaporate the ethanol under a gentle stream of nitrogen and immediately add the solvent of choice. It is recommended that this product be stored and handled in an ethanol solution. Resolvins can isomerize and degrade when put into freeze thaw conditions and/or in solvents such as dimethyl formamide or DMSO.

Description

Resolvins are a family of potent lipid mediators derived from both eicosapentaenoic acid (EPA; Item No. 90110) and docosahexaenoic acid (DHA; Item No. 90310).¹ In addition to being antiinflammatory, resolvins promote the resolution of the inflammatory response back to a non-inflamed state.² RvD1 is produced physiologically from the sequential oxygenation of DHA by 15- and 5-lipoxygenase.¹ A 17(R)-epimer of RvD1 can also be generated in aspirin-treated samples.³ Both RvD1 and its 17(R) configuration reduce human polymorphonuclear leukocyte (PMNL) transendothelial migration, the earliest event in acute inflammation, with EC₅₀ values of ~30 nM.⁴ RvD1 and its aspirin-triggered form also exhibit a dose-dependent reduction in leukocyte infiltration in a mouse model of peritonitis with a maximal inhibition of ~35% at a 10-100 ng dose.4

References

- 1. Hong, S., Gronert, K., Devchand, P.R., et al. J. Biol. Chem. 278(17), 14677-14687 (2003).
- Ariel, A. and Serhan, C.N. TRENDS in Immunology 28(4), 176-183 (2007).
- 3. Serhan, C.N., Hong, S., Gronert, K., et al. J. Exp. Med. 196(8), 1025-1037 (2002).
- 4. Sun, Y.-P., Oh, S.F., Uddin, J., et al. J. Biol. Chem. 282(13), 9323-9334 (2007).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information Buyer agrees to purchase the mater can be found on our website.

Copyright Cayman Chemical Company, 06/14/2019

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM